Zobrazeno 1 - 10
of 437
pro vyhledávání: '"Wells A. Messersmith"'
Autor:
S. Lindsey Davis, Sarah J. Hartman, Stacey M. Bagby, Marina Schlaepfer, Betelehem W. Yacob, Tonia Tse, Dennis M. Simmons, Jennifer R. Diamond, Christopher H. Lieu, Alexis D. Leal, Elaine B. Cadogan, Gareth D. Hughes, Stephen T. Durant, Wells A. Messersmith, Todd M. Pitts
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background AZD0156 is an oral inhibitor of ATM, a serine threonine kinase that plays a key role in DNA damage response (DDR) associated with double-strand breaks. Topoisomerase-I inhibitor irinotecan is used clinically to treat colorectal ca
Externí odkaz:
https://doaj.org/article/800be23a70e04aa88362454d6b8fc5c7
Autor:
Julie Lang, Alexis D. Leal, Juan A. Marín-Jiménez, Sarah J. Hartman, Jeremy Shulman, Natalie M. Navarro, Matthew S. Lewis, Anna Capasso, Stacey M. Bagby, Bethlehem W. Yacob, Morgan MacBeth, Brian M. Freed, S. Gail Eckhardt, Kimberly Jordan, Patrick J. Blatchford, Roberta Pelanda, Christopher H. Lieu, Wells A. Messersmith, Todd M. Pitts
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Immune checkpoint inhibitors have been found to be effective in metastatic MSI-high colorectal cancers (CRC), however, have no efficacy in microsatellite stable (MSS) cancers, which comprise the majority of mCRC cases. Cabozantinib is a small molecul
Externí odkaz:
https://doaj.org/article/4e169c4be6074370bda2cb5901dfda6f
Autor:
Sarah J. Hartman, Stacey M. Bagby, Betelehem W. Yacob, Dennis M. Simmons, Morgan MacBeth, Christopher H. Lieu, S. Lindsey Davis, Alexis D. Leal, John J. Tentler, Jennifer R. Diamond, S. Gail Eckhardt, Wells A. Messersmith, Todd M. Pitts
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with high incidences of p53 mutations. AZD1775 (adavosertib, previously MK-1775) is a small molecule WEE1 inhibitor that abrogates the G2M checkpoint and can potentially synergize with
Externí odkaz:
https://doaj.org/article/3fd57b698eda4a68a4b0e9a0920a5bdc
Autor:
Juan A. Marín-Jiménez, Anna Capasso, Matthew S. Lewis, Stacey M. Bagby, Sarah J. Hartman, Jeremy Shulman, Natalie M. Navarro, Hui Yu, Chris J. Rivard, Xiaoguang Wang, Jessica C. Barkow, Degui Geng, Adwitiya Kar, Ashley Yingst, Dejene M. Tufa, James T. Dolan, Patrick J. Blatchford, Brian M. Freed, Raul M. Torres, Eduardo Davila, Jill E. Slansky, Roberta Pelanda, S. Gail Eckhardt, Wells A. Messersmith, Jennifer R. Diamond, Christopher H. Lieu, Michael R. Verneris, Jing H. Wang, Katja Kiseljak-Vassiliades, Todd M. Pitts, Julie Lang
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Over the past decade, immunotherapies have revolutionized the treatment of cancer. Although the success of immunotherapy is remarkable, it is still limited to a subset of patients. More than 1500 clinical trials are currently ongoing with a goal of i
Externí odkaz:
https://doaj.org/article/6424fe4cd62341bb904d284bc361adfc
Autor:
Peter J. Klauck, Stacey M. Bagby, Anna Capasso, Erica L. Bradshaw-Pierce, Heather M. Selby, Anna Spreafico, John J. Tentler, Aik Choon Tan, Jihye Kim, John J. Arcaroli, Alicia Purkey, Wells A. Messersmith, Keisuke Kuida, S. Gail Eckhardt, Todd M. Pitts
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-12 (2018)
Abstract Background Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. Plk1 is upregulated in many tumor types including colorectal cancer (CRC) and portends a poor prognosis. TAK
Externí odkaz:
https://doaj.org/article/d4dd779ae0964c9eb1a995ae2b3952c9
Autor:
Linfeng Li, Adedoyin D. Abraham, Qiong Zhou, Hadi Ali, Jeremy V. O'Brien, Brayden D. Hamill, John J. Arcaroli, Wells A. Messersmith, Daniel V. LaBarbera
Publikováno v:
Marine Drugs, Vol 12, Iss 9, Pp 4833-4850 (2014)
Recently, we characterized neoamphimedine (neo) as an ATP-competitive inhibitor of the ATPase domain of human Topoisomerase IIα. Thus far, neo is the only pyridoacridine with this mechanism of action. One limiting factor in the development of neo as
Externí odkaz:
https://doaj.org/article/6d9d2518bca44aa38519b5889f365224
Autor:
Colin D. Weekes, Dongweon Song, John Arcaroli, Lora A. Wilson, Belen Rubio-Viqueira, George Cusatis, Elizabeth Garrett-Mayer, Wells A. Messersmith, Robert A. Winn, Manuel Hidalgo
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 8, Pp 690-701 (2012)
PURPOSE: The factors preventing the translation of preclinical findings supporting the clinical development mTOR-targeted therapy in pancreatic cancer therapy remain undetermined. Stromal cell.derived factor 1α (SDF-1α)-CXCR4 signaling was examined
Externí odkaz:
https://doaj.org/article/aba201eee29846aebff0ad9a9f9563f3
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
Autor:
S. Lindsey eDavis, Kelli M. Robertson, Todd M. Pitts, John J. Tentler, Erica L. Bradshaw-Pierce, Peter J. Klauck, Stacey M. Bagby, Stephanie L. Hyatt, Heather M. Selby, Anna eSpreafico, Jeffrey A Ecsedy, John J. Arcaroli, Wells A. Messersmith, Aik Choon eTan, S. Gail eEckhardt
Publikováno v:
Frontiers in Pharmacology, Vol 6 (2015)
Aurora A kinase and MEK inhibitors induce different, and potentially complementary, effects on the cell cycle of malignant cells, suggesting a rational basis for utilizing these agents in combination. In this work, the combination of an Aurora A kina
Externí odkaz:
https://doaj.org/article/5f6654c44590401dbc1d91d387e8147f
Autor:
Hayley J Hawkins, Betelehem W Yacob, Monica E Brown, Brandon R Goldstein, John J Arcaroli, Stacey M Bagby, Sarah J Hartman, Morgan Macbeth, Andrew Goodspeed, Thomas Danhorn, Robert W Lentz, Christopher H Lieu, Alexis D Leal, Wells A Messersmith, Peter J Dempsey, Todd M Pitts
Publikováno v:
PLoS ONE, Vol 19, Iss 4, p e0298808 (2024)
Pancreatic ductal adenocarcinoma (PDAC) presents at advanced stages and is refractory to most treatment modalities. Wnt signaling activation plays a critical role in proliferation and chemotherapeutic resistance. Minimal media conditions, growth fact
Externí odkaz:
https://doaj.org/article/acf54b5fa52843b4b67f450c4a49baa5
Autor:
Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, Wells A. Messersmith, Ignacio Garrido-Laguna, Erkut Borazanci, Andrew M. Lowy, Laura Medina Rodriguez, Daniel Laheru, Beatriz Salvador-Barbero, Marcos Malumbres, David J. Shields, Joseph E. Grossman, Xin Huang, Meggan Tammaro, Jean-François Martini, Yanke Yu, Kenneth Kern, Teresa Macarulla
Publikováno v:
Cancer Research Communications. 2:1326-1333
Purpose: To assess the preclinical efficacy, clinical safety and efficacy, and MTD of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Experimental Design: Preclinical activity was tested in patient-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ee14ce29f5739213957260f92451a25
https://doi.org/10.1158/2767-9764.crc-22-0072
https://doi.org/10.1158/2767-9764.crc-22-0072